Dopaminergic Properties and Experimental Anti-Parkinsonian Effects of IPX750 in Rodent Models of Parkinson Disease

Clinical Neuropharmacology

Volumn 27, Issue 2, 2004, Pages 63-73

  Jiang, Chuantao ^a   Wan, Xinhua ^a   Jankovic, Joseph ^a   Christian, Samuel T ^b   Pristupa, Zdenek B ^c   Niznik, Hyman B ^c   Sundsmo, John S ^b   Le, Weidong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b International Medical Innovations   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anti parkinsonian effects; Dopamine; Dopamine receptors; Glycoconjugate; IPX 750; Parkinson disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOMORPHINE; CYCLIC AMP; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE DERIVATIVE; DOPAMINE GLUCONAMIDE; DOPAMINE GLUCONAMINE; DOPAMINE TRANSPORTER; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; IPX 750; IPX 760; OXIDOPAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN COS7; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG RECEPTOR BINDING; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; ANTIPARKINSON AGENTS; CERCOPITHECUS AETHIOPS; COS CELLS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; GLUCOSE; GLYCOCONJUGATES; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCULOSKELETAL EQUILIBRIUM; PARKINSON DISEASE; PRODRUGS; RECEPTORS, DOPAMINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 2342513603     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200403000-00004     Document Type: Article

References (62)

1. Schultz W, Daylan P, Montague PR. A neural substrate of prediction and reward. Science. 1997;275:1593-1599.
2. Hyman SE. A new image for fear and emotion. Nature. 1998;393:417-418.
3. Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002;58: S19-S32.
4. Martinez D, Broft A, Laruelle M. Imaging neurochemical endophenotypes: promises and pitfalls. Pharmacogenomics. 2001;2:223-237.
5. Mori S, Takanaga H, Ohtsuki S, et al. Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab. 2003;23:432-440.
6. Sampaio-Maia B, Serrao MP, Soares-da-Silva P. Regulatory pathways and uptake of L-DOPA by capillary cerebral endothelial cells, astrocytes, and neuronal cells. Am. J. Physiol. Cell Physiol. 2001;280:C333-C342.
7. Cestelli A, Catania C, D'Agostino S, et al. Functional feature of a novel model of blood brain barrier: studies on permeation of test compounds. J Control Release. 2001;76:139-147.
8. Christian ST. 2003. U.S. Patent Serial No. 2006,548,484.
9. Fernandez C, Nieto O, Fontcnla JA, et al. Synthesis of glycosyl derivatives as dopamine prodrugs: interaction with glucose carrier GLUT-1. Org Biomol Chem. 2003;1:767-771.
10. Fernandez C, Nieto O, Rivas E, et al. Synthesis and biological studies of glycosyl dopamine derivatives as potential antiparkinsonian agents. Carbohydr Res. 2000;327:353-365.
11. Bonina F, Puglia C, Rimoli MG, et al. Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies. J Drug Target. 2003;11:25-36.
12. 3H]-YM-09151-2. Naunyn Schmiedebergs Arch Pharmacol. 1985;329:333-343.
13. Centonze D, Grande C, Usielllo A, et al. Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci. 2003;23:6245-6254.
14. Canales JJ, Iversen SD. Dynamic dopamine receptor interactions in the core and shell of nucleus accumbens differentially coordinate the expression of unconditioned motor behaviors. Synapse. 2000;36:297-306.
15. Swerdlow NR, Martinez ZA, Hanlon FM, et al. Toward understanding the biology of a complex phenotype: Rat strain and substrain differences in the sersorimotor gating-disruptive effects of dopamine agonists. J Neurosci. 2000;20:4325-4336.
16. Sunahara RK, Niznik HB, Weiner DM, et al. Human dopamine D1 receptor encoded by an intronless gene on chromosome 5. Nature. 1990;347:80-83.
17. Sunahara RK, Guan HC, O'Dowd BF, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991;350:614-619.
18. Kumagai AK. Glucose transport in brain and retina: Implications in the management and complications of diabetes. Diabetes Metab Res Rev. 1999;15:261-273.
19. Vannucci SJ, Clark RR, Koehler-Stec E, et al. Glucose transporter expression in brain: Relationship to cerebral glucose utilization. Dev Neurosci. 1998;20:369-379.
20. Grandy DK, Marchionni MA, Makam H, et al. Cloning of the cDNA and gene for the human D2 dopamine receptor. Proc Natl Acad Sci U S A. 1998;86:9762-9766.
21. Sugamori KS, Hamadanizadeh SA, Scheideler MA, et al. Functional differentiation of multiple dopamine D1-like receptors by NNC 01-0012. J Neurochem. 1998;71:1685-1693.
22. Demchyshyn LL, McConkey F, Niznik HB. Dopamine D5 receptor agonist high affinity and constitutive activity profile conferred by carboxyl-terminal tail sequence. J Biol Chem. 2002;275:23446-23455.
23. Seeman P, Van Tol HH. Deriving the therapeutic concentrations of clozapine and haloperidol: The apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing ligand. Eur J Pharmacol. 1995;291:59-66.
24. Pristupa ZB, Wilson JM, Hoffman BJ, et al. Pharmacological heterogeneity of the cloned and native human dopamine transporter: Dissociation of [3H]WIN 35,428 and [3H]-GBR 12,935 binding. Mol Pharmacol. 1994;45:125-135.
25. Pristupa ZB, McConkey F, Liu F, et al. Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse. 1998;30:79-87.
26. Le W, Conneely OM, Zou L, et al. Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol. 1999;159:451-458.
27. 1 receptor blockade and selected pharmacological effects. In: Neurobiology of Central D1 Dopamine Receptors, Eds., G.R. Breese and I. Creese, 1986. Plenum Press, NY. pp. 1-14.
28. 1 receptor antagonists. J Med Chem. 1996;39:3423-3428.
29. 1 dopamine receptor agonist. J Med Chem. 1994;37:2453-2460.
30. Choi SW, Elmaleh DR, Hanson RN, et al. Novel 3-aminomethyl- and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazines: Synthesis and evaluation as dopamine transporter ligands. J Med Chem. 2000;43:205-213.
31. Arita H, Kawanami J. Studies on uptake of phenyl glycosides as inhibitors of D-glucose uptake by Rhesus monkey kidney cells. J Bio Chem. 1980;88:1399-1406.
32. Malmberg A, Jerning E, Mohell N. Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: Evidence for identical binding sites. Eur J Pharmacol. 1996;303:123-128.
33. 2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci. 2000;25:161-166.
34. Le W, Conneely OM, He Y, et al. Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem. 1999;73:2218-2221.
35. Castillo SO, Baffi JS, Palkovits M, et al. Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Mol Cell Neurosci. 1998;11:36-46.
36. Zetterstrom RH, Solomin L, Jansson L, et al. Dopamine neuron agenesis in Nurr1-deficient mice. Science. 1997;276:248-250.
37. Saucedo-Cardenas O, Quintana-Hau JD, Le WD, et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci USA. 1998;95:4013-4018.
38. Le W, Conneely OM, Zou L, et al. Selective agenesis of mesencephalic dopaminergic neurons in Nurr1-deficient mice. Exp Neurol. 1999;159:451-458.
39. Pedrosa R, Soares-da-Silva P. Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. Br J Pharmacol. 2002;137:1305-1313.
40. Khan FH, Saha M, Chakrabarti S. Dopamine induced protein damage in mitochondrial-synaptosomal fraction of rat brain. Brain Res. 2001;895:245-249.
41. Cavalieri EL, Li KM, Balu N, et al. Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis. 2002;23:1071-1077.
42. Li Y, Cao Z. The neuroprotectant ebselen inhibits oxidative DNA damage induced by dopamine in the presence of copper ions. Neurosci Lett. 2002;330:69-73.
43. Paris I, Dagnino-Subiabre A, Marcelain K, et al. Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line. J Neurochem. 2001;77:519-529.
44. Choi HJ, Kim SW, Lee SY, et al. Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease. J Neurochem. 2003;86:143-152.
45. LaVoie MJ, Hastings TG. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci. 1999;19:1484-1491.
46. 2-. J Inorg Biochem. 2001;84:89-96.
47. Chan TS, Moridani M, Siraki A, et al. Hydrogen peroxide supports hepatocyte P450 catalysed xenobiotic/drug metabolic activation to form cytotoxic reactive intermediates. Adv Exp Med Biol. 2001;500:233-236.
48. Lee HJ, Kim SH, Kim KW, et al. Antiapoptotic role of NFκB in the autooxidized dopamine-induced apoptosis of PC12 cells. J Neurochem. 2001; 76:602-609.
49. Seitz G, Stegmann HB, Jager HH, et al. Neuroblastoma cells expressing the noradrenaline transporter are destroyed more selectively by 6-fluorodopamine than by 6-hydroxydopamine. J Neurochem. 2000;75:511-520.
50. Stokes AH, Lewis DY, Lash LH, et al. Dopamine toxicity in neuroblastoma cells: role of glutathione depletion by L-BSO and apoptosis. Brain Res. 2000;858:1-8.
51. Stokes AH, Hastings TG, Vrana KE. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res. 1999;55:659-665.
52. Lyras L, Zeng BY, McKenzie G, et al. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys. J Neural Transm. 2002;109:53-67.
53. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, et al. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem. 2000;74:1605-1612.
54. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigro-striatal neuronal integrity in aged Fischer-344 rats. Neurobiol Aging. 1992;13:339-351.
55. Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neurol Transm. 1997;104:209-228.
56. Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol. 1998;44(Suppl. 1):S167-S174.
57. Sawada H, Ibi M, Kihara T, et al. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol. 1998;44:110-119.
58. Zou LL, Jankovic J, Rowe D, et al. Neuroprotection by pramipexole against dopamine-and levodopa-induced cytotoxicity. Life Sci. 1999;64:1275-1285.
59. Iida M, Miyazaki I, Tanaka K, et al. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 1999;839:51-59.
60. Sethy VH, Wu H, Oostveen JA, et al. Neuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res. 1997;754:181-186.
61. Gille G, Rausch WD, Hung ST, et al. Protection of dopaminergic neurons in primary culture by lisuride. J Neural Transm. 2002;109:157-169.
62. Noh JS, Gwag BJ. Attenuation of oxidative neuronal necrosis by a dopamine D1 agonist in mouse cortical cell cultures. Exp Neurol. 1997;146:604-608.